Plenty of genetic risk factors for sporadic ALS are still waiting to be found, according to a new meta-analysis of GWAS data.
Mutated huntingtin may stow away in synaptic vesicles to sneak from one neuron to another.
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Could tweaking methodologies improve amyloid diagnosis and tracking?
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid ...